AU6266899A - Methods for producing human tumor antigen specific antibodies - Google Patents
Methods for producing human tumor antigen specific antibodiesInfo
- Publication number
- AU6266899A AU6266899A AU62668/99A AU6266899A AU6266899A AU 6266899 A AU6266899 A AU 6266899A AU 62668/99 A AU62668/99 A AU 62668/99A AU 6266899 A AU6266899 A AU 6266899A AU 6266899 A AU6266899 A AU 6266899A
- Authority
- AU
- Australia
- Prior art keywords
- methods
- specific antibodies
- tumor antigen
- human tumor
- antigen specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10314098P | 1998-10-05 | 1998-10-05 | |
US60103140 | 1998-10-05 | ||
PCT/US1999/022314 WO2000020460A1 (en) | 1998-10-05 | 1999-09-28 | Methods for producing human tumor antigen specific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6266899A true AU6266899A (en) | 2000-04-26 |
Family
ID=22293605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU62668/99A Abandoned AU6266899A (en) | 1998-10-05 | 1999-09-28 | Methods for producing human tumor antigen specific antibodies |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1117691A1 (en) |
AU (1) | AU6266899A (en) |
WO (1) | WO2000020460A1 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2378949B (en) | 2001-08-16 | 2005-09-07 | Morten Steen Hanefeld Dziegiel | Recombinant anti-plasmodium falciparum antibodies |
AT411262B (en) | 2001-09-27 | 2003-11-25 | Wolff Klaus Dr | HUMAN ENDOGENIC RETROVIRUS |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
WO2005111208A1 (en) | 2004-04-27 | 2005-11-24 | Chugai Seiyaku Kabushiki Kaisha | Method of proliferating plasma cell |
FR2890859B1 (en) * | 2005-09-21 | 2012-12-21 | Oreal | DOUBLE-STRANDED RNA OLIGONUCLEOTIDE INHIBITING TYROSINASE EXPRESSION |
US8519106B2 (en) * | 2007-03-13 | 2013-08-27 | University Of Zurich | Monoclonal human tumor-specific antibody |
EP2185718B1 (en) * | 2007-08-03 | 2017-10-04 | MUSC Foundation For Research Development | Human monoclonal antibodies and methods for producing the same |
EP2316936B1 (en) * | 2008-06-04 | 2013-08-07 | Shizuoka Prefecture | Method for analysis/identification of antibody gene at one-cell level |
CN101885758B (en) * | 2009-05-11 | 2014-04-30 | 中国医学科学院肿瘤研究所 | Auto-antigen epitope and encoding gene and application thereof |
EP2714742A1 (en) * | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
US20140287402A1 (en) * | 2011-06-27 | 2014-09-25 | Valneva | Method for screening cells |
AU2016275030B2 (en) | 2015-06-10 | 2021-12-09 | Nantkwest, Inc. | Modified NK-92 cells for treating cancer |
EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | Methods of treating cancer with interferon |
JP2019532640A (en) | 2016-09-29 | 2019-11-14 | ナントクエスト インコーポレイテッド | HLA class I deficient NK-92 cells with reduced immunogenicity |
EP3565889A4 (en) | 2017-01-06 | 2020-12-16 | Nantkwest, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
EP3703735A1 (en) | 2017-11-01 | 2020-09-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
DE112019000608B4 (en) | 2018-01-31 | 2021-05-06 | Nantkwest, Inc. | USE OF 5% HUMAN ALBUMIN IN WASHING AND HARVESTING MEDIA |
WO2019177986A1 (en) | 2018-03-12 | 2019-09-19 | Nantkwest, Inc. | Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity) |
KR102587512B1 (en) | 2018-05-22 | 2023-10-11 | 이뮤너티바이오, 인크. | Optimization of NK-92 cell growth using poloxamers |
JP2021525073A (en) | 2018-05-22 | 2021-09-24 | ナントケーウエスト,インコーポレイテッド | Fc Epsilon CAR |
KR20210011977A (en) | 2018-05-22 | 2021-02-02 | 난트케이웨스트, 인크. | Basal medium for growing NK-92 cells |
EP3820994A1 (en) | 2018-07-10 | 2021-05-19 | Nantkwest, Inc. | Generating cik nkt cells from cord blood |
US20210267190A1 (en) | 2018-07-10 | 2021-09-02 | Nantkwest, Inc. | Cryopreservation |
KR102653878B1 (en) | 2018-08-01 | 2024-04-01 | 난트퀘스트, 인크. | A QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR OR A CYTOKINE, AND CHIMERIC ANTIGEN RECEPTOR FOR GENETIC MODIFICATION OF IMMUNOTHERAPIES |
US20210293787A1 (en) | 2018-08-01 | 2021-09-23 | Nantkwest, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
CA3107101A1 (en) | 2018-08-01 | 2020-02-06 | Nantkwest, Inc. | Chemokine responsive activated natural killer cells with secondary homing activation for verified targets |
CA3092305A1 (en) | 2018-11-06 | 2020-05-14 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells |
AU2019388876A1 (en) | 2018-11-26 | 2021-05-20 | Immunitybio, Inc. | IL-2 Dependent NK-92 cells with stable Fc receptor expression |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
WO2023081163A1 (en) | 2021-11-02 | 2023-05-11 | Immunitybio, Inc. | Natural killer cells for chordoma therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5673794A (en) * | 1992-11-19 | 1994-06-08 | Matthew C. Biery | Production of monoclonal recombinant antibodies without the use of hybridomas by (in vitro) spleen fragment culture combined with isothermal self-sustained sequence replication of rna |
-
1999
- 1999-09-28 AU AU62668/99A patent/AU6266899A/en not_active Abandoned
- 1999-09-28 EP EP99949891A patent/EP1117691A1/en not_active Withdrawn
- 1999-09-28 WO PCT/US1999/022314 patent/WO2000020460A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2000020460A1 (en) | 2000-04-13 |
EP1117691A1 (en) | 2001-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6266899A (en) | Methods for producing human tumor antigen specific antibodies | |
AU1462300A (en) | Human pan-hcv human monoclonal antibodies | |
AU1704099A (en) | Monoclonal human natural antibodies | |
TWI365193B (en) | Human antibodies that bind human il-12 and methods for producing | |
AU3596599A (en) | Method for producing antibody fragments | |
ZA9810130B (en) | Tumor-specific antigens methods for their production and their use for imunization and diagnosis | |
AU5686698A (en) | Methods for the production of chicken monoclonal antibodies | |
AU5441000A (en) | Human monoclonal antibody | |
AU2002349543A1 (en) | Tumor antigens | |
AU2948199A (en) | Breast cancer antigen | |
AU9374198A (en) | Methods for producing human antibodies in scid mice using dendritic cells | |
EP0977590A4 (en) | Human monoclonal antibodies | |
AU7572198A (en) | Tumor-associated antigen | |
AU2452301A (en) | Protein methylarginine-specific antibodies | |
GB9804065D0 (en) | Tumour associated antigen 791Tgp72 | |
AU5046700A (en) | Diagnostic monoclonal antibody for LTiGTyersinia pestisLT/iGT | |
ZA941645B (en) | Antibodies specifically reactive against human prostate specific antigen. | |
AU3416599A (en) | Casb414: antigen overexpressed in several tumors | |
AU2001245552A1 (en) | Transcutaneous immunization for large particulate antigens | |
AU1809695A (en) | Tumor associated monoclonal antibody 123av16 | |
AU7128098A (en) | Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies | |
AU2169797A (en) | Improved production of antibodies through the use of antigen antibody complexes | |
AU4775899A (en) | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production | |
EP1446416A4 (en) | Tumor specific monoclonal antibodies | |
AU1370300A (en) | Antigen-binding fragments specific for tumor associated antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |